If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The study met its primary endpoint and all 11 secondary efficacy endpoints
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Patients can now get the starting 2.5 mg dose for $299 per month
Subscribe To Our Newsletter & Stay Updated
